HBM Healthcare Investments (HBMN.SW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

HBMN.SW · Stock Price

CHF 234.00+61.20 (+35.42%)

Market Cap: $2.0B

Historical price data

Market Cap: $2.0BFounded: 2001HQ: Zug, Switzerland

Sector Ranking#46 in Digital Health & Biotech SaaS

Overview

HBM Healthcare Investments AG is a Swiss investment company with a mission to generate long-term capital growth by investing in a globally diversified portfolio of private and public healthcare companies. Its core strategy combines proprietary deal flow, active portfolio management, and deep sector expertise to guide promising companies from late-stage private rounds through to public listings and trade sales. A key recent achievement includes the announced acquisition of portfolio company Terns Pharmaceuticals by Merck, Sharp & Dohme for USD 6.7 billion, validating its investment selection and value-creation approach.

OncologyNeurologyDiagnosticsMedical Technology

Technology Platform

An investment and value-creation platform built on deep sector expertise, proprietary deal flow, and active portfolio management through board participation, rather than a therapeutic technology.

Funding History

1

IPOUndisclosedUndisclosedJun 15, 2001

Opportunities

The company is poised to capitalize on sustained healthcare sector growth driven by demographics and innovation, alongside a robust biopharma M&A environment that can generate significant exits.

Its hybrid private/public model offers investors unique access to pre-IPO opportunities within a liquid, publicly-traded vehicle.

Risk Factors

Key risks include volatility in the biotech sector impacting portfolio valuations, the potential for a persistent or widening discount of share price to Net Asset Value (NAV), and the illiquidity and subjective valuation challenges associated with its private company holdings.

Competitive Landscape

HBM competes with other healthcare-focused closed-end funds and asset managers, differentiating itself through a strong emphasis on active ownership in private companies, deep sector expertise, and a hybrid portfolio strategy that blends private and public equity exposure.